A 33

Product Description

A 33 is a potent and selective PDE4B inhibitor (IC₅₀ = 15 nM); exhibits >100-fold selectivity for PDE4B over 4D. Regulates cAMP in inflammatory cells. Inhibits LPS-induced TNF-α production and neutrophil accumulation in mouse lungs. Reduces microglial and neutrophil activation, and improves behavioral deficits in a traumatic brain injury model in vivo. Also exhibits antidepressant-like effects. Orally bioavailable.

Solubility

Preparing Stock Solutions for A 33

The following data is based on the product molecular weight 387.88

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.58 mL	12.89 mL	25.78 mL
5 mM	0.52 mL	2.58 mL	5.16 mL
10 mM	0.26 mL	1.29 mL	2.58 mL
50 mM	0.05 mL	0.26 mL	0.52 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Zhang Comparison of the pharmacological profiles of selective PDE4B and PDE4D inhibitors in the central nervous system. Sci.Rep. 2017 PMID: 28054669
• Wilson Therapeutic benefits of phosphodiesterase 4B inhibition after traumatic brain injury. PLoS One 2017 PMID: 28542295
• Naganuma Discovery of selective PDE4B inhibitors. Bioorg.Med.Chem.Lett. 2009 PMID: 19447034